mercaptopurine and Coronary-Restenosis

mercaptopurine has been researched along with Coronary-Restenosis* in 1 studies

Other Studies

1 other study(ies) available for mercaptopurine and Coronary-Restenosis

ArticleYear
Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation.
    Circulation, 2007, Jan-30, Volume: 115, Issue:4

    Restenosis is a common complication after percutaneous coronary interventions and is characterized by excessive proliferation of vascular smooth muscle cells (SMCs). We have shown that the nuclear receptor Nur77 protects against SMC-rich lesion formation, and it has been demonstrated that 6-mercaptopurine (6-MP) enhances Nur77 activity. We hypothesized that 6-MP inhibits neointima formation through activation of Nur77.. It is demonstrated that 6-MP increases Nur77 activity in cultured SMCs, which results in reduced [3H]thymidine incorporation, whereas Nur77 small interfering RNA knockdown partially restores DNA synthesis. Furthermore, we studied the effect of 6-MP in a murine model of cuff-induced neointima formation. Nur77 mRNA is upregulated in cuffed arteries, with optimal expression after 6 hours and elevated expression up to 7 days after vascular injury. Local perivascular delivery of 6-MP with a drug-eluting cuff significantly inhibits neointima formation in wild-type mice. Locally applied 6-MP does not affect inflammatory responses or apoptosis but inhibits expression of proliferating cell nuclear antigen and enhances protein levels of the cell-cycle inhibitor p27(Kip1) in the vessel wall. An even stronger inhibition of neointima formation in response to local 6-MP delivery was observed in transgenic mice that overexpressed Nur77. In contrast, 6-MP does not alter lesion formation in transgenic mice that overexpress a dominant-negative variant of Nur77 in arterial SMCs, which provides evidence for the involvement of Nur77-like factors.. Enhancement of the activity of Nur77 by 6-MP protects against excessive SMC proliferation and SMC-rich neointima formation. We propose that activation of the nuclear receptor Nur77 is a rational approach to treating in-stent restenosis.

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cells, Cultured; Coronary Restenosis; Disease Models, Animal; DNA-Binding Proteins; Drug Implants; Femoral Artery; Humans; Male; Mercaptopurine; Mice; Mice, Inbred Strains; Mice, Transgenic; Muscle, Smooth, Vascular; Nuclear Receptor Subfamily 4, Group A, Member 1; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; RNA, Small Interfering; Transcription Factors; Tunica Intima; Umbilical Arteries

2007